Physicians and cancer researchers in Heidelberg and Mannheim have for the first time carried out a clinical trial to test a cancer vaccine candidate that targets a specific mutation in the isocitrate dehydrogenase 1 (IDH1) gene. Results from the first-in-human Phase I study in glioma patients showed that repeated injections of the peptide vaccine were safe, and triggered the anticipated immune response in the patients' tumor tissue.
Investigators in a multinational study scanned genomes of nearly 200,000 people to find interactions with genes and sex for schizophrenia, major depressive disorder, and bipolar disorder. These new findings will help identify potential targets for sex-dependent or sex-specific therapeutic interventions creating more effective therapies for both sexes.
A new nanoparticle flu vaccine platform simplifies construction of multivalent immunogens and offers broad protection, blocking seasonal and pandemic strains. A well-ordered mosaic immunogen that has been generated with the platform is to be assessed in a Phase I trial. If the trial succeeds, it would signal progress toward a universal flu vaccine.
Proceeds will be used to support the company’s GMP capabilities in cell and gene therapy and monoclonal antibody bioprocessing.
aTyr’s primary focus is ATYR1923, a clinical-stage product candidate, which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.
Researchers have moved one step closer to understanding the connection between the microbiome and immunotherapy through the discovery that the immune system recognizes bacteria residing in tumors. In addition, the bacteria can be harnessed to provoke an immune reaction against the tumor.
The pharma giant released results from the Phase III D8110C00001 trial (NCT04516746), showing the vaccine to be 79% effective at preventing symptomatic COVID-19 and 100% effective at preventing severe disease or hospitalization in the whole cohort. The positive safety and efficacy results from the 32,449-participant Phase III study in the U.S., Chile, and Peru for its COVID-19 vaccine—and specifically, no increased risk of blood clots along the lines of the 30 reported in Europe earlier this month.
Anima specializes in treating targets long viewed as “undruggable” by targeting cellular mechanisms that regulate mRNA translation of proteins with specific biological roles in coordinating and regulating translation of individual mRNAs and pathways.
The company also will build biomanufacturing capacity to help accelerate the preclinical and clinical development of its therapeutic antibodies, which are complementary to vaccination.
Scientists at the Ohio State University Wexner Medical Center, College of Engineering and College of Medicine have developed a nonviral tissue nanotransfection technique that effectively reprograms skin cells to become vascular cells, generating new blood vessels to boost blood delivery to the damaged tissue. The researchers suggest that the strategy may someday be used to help patients regain speech, cognition, and motor function, even when administered days after an ischemic stroke.